LSE:GSKPharmaceuticals
GSK Approvals For Depemokimab Highlight Shift Toward Respiratory And Oncology Growth
GSK (LSE:GSK) secures approvals for depemokimab from the European Commission and China’s NMPA, adding to existing authorisations in the United States, Japan, and the UK.
Depemokimab is described as the first ultra long acting biologic for its indications in respiratory and inflammatory diseases.
The company also reports positive phase 1 data for Mo-Rez, an antibody drug conjugate being studied in difficult to treat gynecologic cancers.
For readers following large pharma, GSK (LSE:GSK)...